Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 534 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sleep Control Condition Clear all
Completed Phase 2 Interventional

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Results available

Tailored Intervention to Promote Positive Airway Pressure Adherence

NCT01454830
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Patient Compliance
Interventions
Tailored, Usual care
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

NCT00352144
View directory record Official record
Conditions
Primary Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
58
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jun 26, 2026, 4:05 AM EDT
Terminated Not applicable Interventional

Effect of Oral Appliance Therapy on Atrial Fibrillation

NCT03835429
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
MyTAP oral appliance plus mouth shield
Device
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.

NCT00671294
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon and Placebo (9 possible combinations total)
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Hot Springs, Arkansas • Irvine, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Jun 26, 2026, 4:05 AM EDT
Withdrawn Phase 4 Interventional

Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

NCT04205136
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

NCT03001557
View directory record Official record
Conditions
Irregular Sleep-Wake Rhythm Disorder
Interventions
Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jun 26, 2026, 4:05 AM EDT
Terminated Early Phase 1 Interventional

Effects of Melatonin in Untreated Obstructive Sleep Apnea

NCT03492736
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
Naomi Deacon
Other
Eligibility
30 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

AD109 Dose Finding in Mild to Moderate OSA

NCT04631107
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109 dose1- A, AD109 dose2- B, Placebo- C
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Diego, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

NCT02952820
View directory record Official record
Conditions
Insomnia Disorder
Interventions
lemborexant, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
42
States / cities
Chandler, Arizona • Rogers, Arkansas • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jun 26, 2026, 4:05 AM EDT
Recruiting Not applicable Interventional

Adapted CBT-I for Adolescents With Insomnia : The DREAM-IT Study

NCT06541886
View directory record Official record
Conditions
Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
13 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

NCT05668754
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Serdexmethylphenidate, Placebo
Drug · Other
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jun 26, 2026, 4:05 AM EDT
Recruiting Not applicable Interventional

Effect of ANNE One-Wellue Device Array Use on Staff Bedside Vital Sign Measurement Activity

NCT06995742
View directory record Official record
Conditions
Vital Sign Evaluation, Vital Sign Monitoring, Sleep Quality, Provider Behavior, Patient Satisfaction
Interventions
Device Array Use, Routine Vital Sign Measurement
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 26, 2026, 4:05 AM EDT
Recruiting Phase 4 Interventional

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

NCT02630121
View directory record Official record
Conditions
Sleep Apnea, Chronic Nasal Congestion
Interventions
Oxymetazoline Hydrochloride, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

NCT02729714
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Burdick, Daniel, M.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

NCT03030599
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
JZP-258, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Orange, California • Stanford, California • Boulder, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Jun 26, 2026, 4:05 AM EDT
Not listed Not applicable Interventional

Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia

NCT00415714
View directory record Official record
Conditions
Primary Insomnia
Interventions
Portable Biofeedback
Device
Lead sponsor
Helicor
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2007 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

NCT03545191
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
36
States / cities
Anniston, Alabama • Birmingham, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

NCT01096680
View directory record Official record
Conditions
Sleep Deprivation
Interventions
SPD489 20 mg, SPD489 50 mg, SPD489 70 mg, Armodafinil, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jun 26, 2026, 4:05 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

NCT03109418
View directory record Official record
Conditions
Sleep Apnea, Obstructive Sleep Apnea, Postoperative Complications
Interventions
Ketamine, Control
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Not applicable Interventional Results available

Trial on the Effect of Optically Modified Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain

NCT00969540
View directory record Official record
Conditions
Back Pain, Insomnia
Interventions
Active Mattress Cover, Placebo Mattress Cover
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jun 26, 2026, 4:05 AM EDT
Not listed Not applicable Interventional

The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)

NCT04462796
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Magnesium Citrate
Dietary Supplement
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

NCT03034018
View directory record Official record
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Jun 26, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

NCT05233761
View directory record Official record
Conditions
Insomnia
Interventions
Defined CBD, Placebo
Drug
Lead sponsor
Defined Research
Industry
Eligibility
25 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 26, 2026, 4:05 AM EDT